The treatment of multiple sclerosis has made enormous progress thanks to highly effective disease-modifying therapies, in particular anti-CD20 antibodies. For most newly diagnosed patients, a life without disability is realistic. However, the focus is now shifting from preventing acute relapses to combating the insidious progression of disability. New approaches target cellular mechanisms in the CNS and the promotion of remyelination.
Autoren
- Dr. Ulf Blanke
Publikation
- InFo NEUROLOGIE & PSYCHIATRIE
You May Also Like
- Migraine
Fremanezumab for comorbid migraine and depression
- Case study
Moyamoya disease in a 23-year-old female patient
- Dapagliflozin for T2D and heart failure
Epicardial fat reduced in patients with type 2 diabetes and HF
- A hub of biological aging
Mitochondrial dysfunction and energy metabolism
- Health Literacy
Promoting health literacy: from the abstract to the concrete level
- Pharmacological therapy
Anxiety symptoms in eating disorders
- Case study
Wiedemann-Steiner syndrome in a 2-year-old girl
- Evidence, limitations and practical implications